Table
From: Safety of anti-TNF therapy: 10 year experience in pediatric patients from a single tertiary center
Etanercept | Infliximab | Adalimumab | |
|---|---|---|---|
Number of treatments | 105 | 43 | 12 |
Mean age at onset,ys (SD) | 11.2 (4.8) | 12.5 (4.1) | 16.4 (3.8) |
Exposure time (pts-year) | 246,5 | 82,7 | 9,2 |
Adverse events | 75 | 76 | 5 |
Incidente rate AE | 0.3 | 0.9 | 0.5 |
SAE (incidente rate) | 2 (0.008) | 5 (0.06) | 0 (0) |
Opportunistic infections (Tuberculosis) | 1 | 2 | 0 |
Discontinuation due to AE n (%) | 5 (4.8) | 13 (30.2) | 0 |